News Sentiment

ADCT sentiment intelligence

ADC Therapeutics SA news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 57 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.29 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+8.4% over one week, +22.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 8.4% Price confirming higher
Trend fit Trend inactive 22.9% over four weeks
Fair value -53.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 34
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 8
PR Newswire 7
TradingView 6
ACCESS Newswire 4
MT Newswires 3
simplywall.st 3
grafa.com 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 17
Regulatory and legal 6
Balance sheet 3
Analyst action 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Moomoo Direct company coverage

Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

This press release details ADC Therapeutics' financial results for the first quarter of 2026 and provides operational updates. It likely includes key financial figures such as revenue, net income/loss, and expenses, along with information on clinical trial progress, regulatory su

Tone
Positive 76/100
Event
Earnings
Published
11 Jul 2026 12:10
Source
Moomoo
Stock Titan Direct company coverage

ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award

ADC Therapeutics (ADCT) has granted its CFO, Jose Carmona, 203,700 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs will vest on June 30, 2027, or earlier under specific termination events, provided continued employment. This award increas

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 09:40
Source
Stock Titan
Stock Titan Direct company coverage

ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing

ADC Therapeutics SA's CEO, Ameet Mallik, was granted 675,000 restricted stock units (RSUs) on June 30, 2026, as reported in a Form 4 SEC filing. These RSUs, which have a price of $0.00 per unit, will vest on the earlier of June 30, 2027, or upon certain qualifying terminations of

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares

ADC Therapeutics' Chief Medical Officer, Zaki Mohamed, was granted 213,900 Restricted Stock Units (RSUs) on June 30, 2026, as an equity award. This compensation-related grant increases his direct holdings to 896,317 common shares. The RSUs will vest on the earlier of June 30, 202

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer

ADC Therapeutics (ADCT) announced that its Chief Legal Officer, Peter J. Graham, was granted 221,100 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs, which represent common shares, will vest on the earlier of June 30, 2027, or specific te

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Stock Titan
PR Newswire Direct company coverage

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics SA (NYSE: ADCT) has announced an inducement grant of options to purchase 17,000 common shares for a new employee. This grant, approved by the Compensation Committee, aims to retain top talent and relies on the employment inducement exemption under the NYSE's List

Tone
Positive 65/100
Event
Market update
Published
01 Jul 2026 20:05
Source
PR Newswire
BioPharm International Direct company coverage

ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL

ADC Therapeutics has completed enrollment of 100 patients in its Phase 1b LOTIS-7 trial, evaluating a combination of ZYNLONTA and glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial has shown an 89.8% overall response rate and a 77.6% complete resp

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 18:10
Source
BioPharm International
grafa.com Direct company coverage

ADC Therapeutics completes LOTIS-7 trial enrollment

ADC Therapeutics has completed enrollment for its Phase 1b LOTIS-7 clinical trial, which investigates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 100 patients and aims to assess the saf

Tone
Positive 68/100
Event
Market update
Published
30 Jun 2026 14:10
Source
grafa.com
Investing.com Direct company coverage

ADC Therapeutics completes enrollment in LOTIS-7 trial

ADC Therapeutics has completed enrollment in its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The company reported promising initial response rates from earlier data and anticipates s

Tone
Positive 60/100
Event
Macro sensitivity
Published
30 Jun 2026 12:10
Source
Investing.com
PR Newswire Direct company coverage

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

ADC Therapeutics announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA® in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients at the selected 150 µg/kg dose

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 11:10
Source
PR Newswire
TradingView Direct company coverage

ETFs Investing in ADC Therapeutics Ltd Stocks

This article lists several ETFs that hold ADC Therapeutics Ltd (ADCT) stocks, providing financial details for each fund. The ETFs include those focused on small-cap growth, biotechnology, micro-cap companies, and healthcare innovation, with varying management styles and expense r

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 16:41
Source
TradingView
marketscreener.com Direct company coverage

ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index

ADC Therapeutics SA (ADCT) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement on the same day that the company was added to the Russell 2000 Value Benchmark. The company, a clinical-stage oncology drug developer, recently repor

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 13:41
Source
marketscreener.com
Stock Titan Direct company coverage

ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma

ADC Therapeutics (NYSE: ADCT) has completed enrollment for its LOTIS-7 Phase 1b trial, which evaluates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients across 30 sites, buil

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 12:41
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT

This article provides financial information for ADC Therapeutics SA (NYSE: ADCT), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of TradingView's platform, indicating that the metrics are available for investor an

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT

This article provides a brief financial data point for ADC Therapeutics SA (NYSE:ADCT), specifically regarding its price-to-earnings forward ratio. The content is sparse, indicating "Period Value Change Change %" but without specific numerical data. It appears to be a stub or a s

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 00:11
Source
TradingView
TradingView Direct company coverage

ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT)

This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price targets, upcoming earnings dates, and past financial results lik

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
grafa.com Direct company coverage

ADC Therapeutics launches restructuring around ZYNLONTA

ADC Therapeutics (NYSE:ADCT) is undergoing a strategic reorganization focusing on its ZYNLONTA franchise and related clinical trials. The restructuring involves an estimated 17% workforce reduction, expected to save $10 million annually, and aims to extend the company's cash runw

Tone
Neutral 50/100
Event
Balance sheet
Published
24 Jun 2026 16:11
Source
grafa.com
TradingView Direct company coverage

ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges

ADC Therapeutics announced a global workforce reduction of approximately 17% to achieve about $10 million in annualized cost savings. This reduction is primarily due to the completion of the LOTIS-5 and LOTIS-7 programs and aims to enhance financial flexibility. The company expec

Tone
Positive 65/100
Event
Market update
Published
24 Jun 2026 13:11
Source
TradingView
Stock Titan Direct company coverage

ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway

ADC Therapeutics announced a strategic reorganization involving a 17% global workforce reduction to focus on its ZYNLONTA franchise. This move is expected to generate $10 million in annualized cost savings against $3 million in one-time charges, extending the company’s cash runwa

Tone
Neutral 50/100
Event
Balance sheet
Published
24 Jun 2026 13:11
Source
Stock Titan
PR Newswire Direct company coverage

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

ADC Therapeutics (NYSE: ADCT) has announced a strategic reorganization, including a 17% global workforce reduction, to enhance financial flexibility and focus on ZYNLONTA® growth. The company expects to save approximately $10 million annually, driven by the anticipated completion

Tone
Positive 64/100
Event
Guidance
Published
24 Jun 2026 11:11
Source
PR Newswire
Stocktwits Direct company coverage

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

ADC Therapeutics (ADCT) announced a 17% workforce reduction to focus on its ZYNLONTA franchise and upcoming regulatory milestones, including a pre-supplemental Biologics License Application with the FDA in August 2026. This move is expected to generate $10 million in annualized c

Tone
Negative 35/100
Event
Regulatory and legal
Published
24 Jun 2026 09:13
Source
Stocktwits
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) following a significant drop in stock price. This investigation comes after ADC announced topline data from its Phase 3 LOTIS-5 trial, where their treatment,

Tone
Negative 18/100
Event
Regulatory and legal
Published
23 Jun 2026 05:10
Source
ACCESS Newswire